导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -18.83% | 4309/4773 |
| 近一周 | -3.38% | 4721/5465 |
| 近一月 | -1.81% | 1316/5421 |
| 近一季 | -8.13% | 3117/5231 |
| 近半年 | -23.46% | 4627/4920 |
| 近一年 | -12.01% | 3517/4394 |
| 近两年 | 29.46% | 2303/2954 |
| 近三年 | 0.80% | 1913/2253 |
| 成立以来 | 45.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.73% 1931/4961 |
-17.69% 4781/5312 |
- - |
- - |
| 2025 | 28.75% 1456/4813 |
6.02% 691/3635 |
-2.23% 3329/4076 |
16.37% 2659/4524 |
6.73% 341/4813 |
| 2024 | 3.54% 1919/3463 |
1.14% 897/2808 |
-6.28% 1903/3014 |
10.71% 2601/3129 |
-1.34% 1661/3463 |
| 2023 | -4.88% 701/2656 |
2.78% 1298/2280 |
-5.54% 1493/2385 |
2.87% 213/2515 |
-4.76% 1161/2655 |
| 2022 | -21.43% 1033/2207 |
-8.69% 290/1919 |
0.70% 1531/2016 |
-15.25% 1251/2113 |
0.82% 1446/2208 |
| 2021 | 43.32% 18/1822 |
16.88% 2/1255 |
9.48% 550/1330 |
20.12% 45/1466 |
-6.76% 1549/1822 |
| 2020 | 15.66% 781/1250 |
-9.50% 683/1028 |
7.63% 836/1067 |
8.67% 702/1164 |
9.27% 648/1184 |
| 2019 | 3.62% 801/1092 |
19.64% 622/754 |
-9.36% 648/804 |
-8.39% 828/850 |
4.31% 812/918 |
| 2018 | -27.41% 420/834 |
- - |
- - |
- - |
-16.80% 642/691 |
| 2017 | 15.38% 246/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.69% 202/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 鹏华国证钢铁行业指数(LOF)A VS. 长安沪深300非周期A(740101) |